Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

doi:10.4254/wjh.v14.i8.1562

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3302)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

144

WORD

HTML

1471

Figures (1-2)

334

Tables (1-6)

369

Sum=2358

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

212

Download

732

Sum=944

Aug 27, 2022 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Aug 27, 2022; 14(8): 1562-1575
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1562

Table 5 Survival analysis

		Dead, N = 34	Median (95%CI)of the EstimatedSurvival Time	Log rank (Mantel-Cox)	P value
Gender	Female (%)	9 (26.5)	315.0 (134.4- 495.6)	0.094	0.8
Gender	Male (%)	25 (73.5)	441.0 (329.7- 552.3)	0.094	0.8
Smoker	No (%)	29 (85.3)	395.0 (299.9- 490.1)	1.595	0.2
Smoker	Yes (%)	5 (14.7)	581.0 (336.4- 825.6)	1.595	0.2
DM	No (%)	27 (79.4)	413.0 (341.7- 484.3)	0.259	0.6
DM	Yes (%)	7 (20.6)	429.0 (257.4- 600.6)	0.259	0.6
BCLC stages	Early (%)	12 (35.3)	532.0 (401.2- 662.8)	5.594	0.05^a
	Intermediate (%)	14 (41.2)	393.0 (225.7- 560.3)
	Late (%)	8 (23.5)	284.0 (196.6- 371.4)
Performance status	0 (%)	21 (61.8)	395.0 (314.6 - 475.4)	1.188	0.6
	1 (%)	12 (35.3)	516.0 (404.0- 628.0)
	2 (%)	1 (2.9)	278.0 (278.0- 278.0)
	3	0 (0.0)	-
Child score	A (%)	26 (76.5)	429.0 (316.6- 541.4)	0.574	0.8
	B (%)	7 (20.6)	375.0 (241.9- 508.1)
	C (%)	1 (2.9)	516.0 (516.0- 516.0)
Response to treatment mRECIST	Stationary	4 (11.8%)	284.0 (215.4- 352.6)	2.9	0.4
	Partial response	1 (2.9%)	412.0 (412.0- 412.0)
	Complete response	19 (55.9%)	456.0 (346.7- 565.3)
	Progressive disease	5 (14.7%)	128.0 (0.0- 285.2)
miRNA-326 >1.165			441.0 (336.7- 545.3)	17.1	0.001^b
miRNA-511<2.063			441.0 (329.5- 552.5)	0.626	0.4
miRNA-424>2.462			395.0 (300.7- 489.3)	2.707	0.1

mRECIST: Modified Response Evaluation Criteria in Solid Tumors; BCLC: Barcelona Clinic Liver Cancer; DM: Diabetes mellitus; 95%CI: 95%Confidence interval.

^aP value < 0.05 is significant.

^bP value < 0.01 is highly significant.

Citation: Youssef SS, Elfiky A, Nabeel MM, Shousha HI, Elbaz T, Omran D, Marie MS, Elzahry MA, Abul-Fotouh A, Hashem A, Guda MF, Abdelaziz AO. Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians. World J Hepatol 2022; 14(8): 1562-1575
URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1562.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1562